A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,700 shares of IPSC stock, worth $10,527. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,700
Previous 7,000 24.29%
Holding current value
$10,527
Previous $17,000 17.65%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.44 - $3.29 $38,410 - $87,757
-26,674 Reduced 59.07%
18,486 $31,000
Q2 2024

Aug 14, 2024

SELL
$2.46 - $4.05 $22,464 - $36,984
-9,132 Reduced 16.82%
45,160 $115,000
Q1 2024

May 15, 2024

SELL
$3.19 - $5.32 $145,550 - $242,735
-45,627 Reduced 45.66%
54,292 $226,000
Q4 2023

Feb 14, 2024

BUY
$1.28 - $3.32 $52,899 - $137,208
41,328 Added 70.54%
99,919 $331,000
Q3 2023

Nov 14, 2023

BUY
$2.0 - $3.23 $68,292 - $110,291
34,146 Added 139.69%
58,591 $117,000
Q2 2023

Aug 14, 2023

SELL
$2.91 - $3.53 $80,767 - $97,975
-27,755 Reduced 53.17%
24,445 $77,000
Q1 2023

May 15, 2023

SELL
$3.4 - $5.11 $268,457 - $403,475
-78,958 Reduced 60.2%
52,200 $181,000
Q4 2022

Feb 14, 2023

BUY
$4.84 - $11.58 $634,804 - $1.52 Million
131,158 New
131,158 $672,000

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $71.2M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.